Literature DB >> 20063131

Autoimmune haemolytic anaemia associated with mantle cell lymphoma.

Heather E Eve1, Simon A J Rule.   

Abstract

Autoimmune haemolytic anaemia (AIHA) is a well-recognised complication of lymphoproliferative disorders, and has been reported in association with all B and T cell non-Hodgkin lymphoma subtypes with the exception of mantle cell lymphoma (MCL). We describe herein a case of MCL diagnosed in an initially asymptomatic 66-year-old woman who developed transfusion-dependent AIHA 6 months later coincident with lymphoma progression. The AIHA failed to respond satisfactorily to conventional treatment (high-dose oral prednisolone) but rapidly resolved following commencement of non-rituximab-containing combination chemotherapy in parallel with complete remission of the lymphoma. This is the first of such cases to be described in the literature and confirms that the immune environment of MCL can predispose to AIHA in the same way as in other lymphoma subtypes. Despite this being an infrequent occurrence, clinicians should be aware that AIHA is a potential complication of MCL and may be more successfully controlled by treating the underlying lymphoma rather than relying on conventional anti-haemolytic strategies such as steroids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063131     DOI: 10.1007/s12185-009-0489-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  13 in total

1.  Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy.

Authors:  P Rossi; A L Demoux; B Granel; D Bagnères; S Bonin-Guillaume; Y Frances
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

2.  Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies.

Authors:  Akinori Hara; Takashi Wada; Shinji Kitajima; Tadashi Toyama; Toshiya Okumura; Kiyoki Kitagawa; Yasunori Iwata; Norihiko Sakai; Kengo Furuichi; Masato Higuchi; Shuichi Kaneko
Journal:  Am J Hematol       Date:  2008-09       Impact factor: 10.047

3.  Autoimmune haemolytic anaemia--an under-recognized risk factor for venous thromboembolism.

Authors:  J Thachil
Journal:  Transfus Med       Date:  2008-12       Impact factor: 2.019

4.  Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.

Authors:  Heather E Eve; Michelle V Furtado; Michael D Hamon; Simon A J Rule
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

5.  Epstein-Barr virus associated diffuse large B-cell lymphoma complicated by autoimmune hemolytic anemia and pure red cell aplasia.

Authors:  H Katayama; M Takeuchi; T Yoshino; M Munemasa; A Tada; R Soda; K Takahashi
Journal:  Leuk Lymphoma       Date:  2001-07

6.  Splenic lymphoma presenting as warm autoimmune hemolytic anemia associated with pure red cell aplasia.

Authors:  A Zeidman; Z Fradin; Y Barac; D Bendayan; M Mittelman; J Orlin
Journal:  Vox Sang       Date:  2000       Impact factor: 2.144

Review 7.  Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas.

Authors:  Alexander W Hauswirth; Cathrin Skrabs; Christian Schützinger; Alexander Gaiger; Klaus Lechner; Ulrich Jäger
Journal:  Leuk Lymphoma       Date:  2007-06

8.  Outcome of deferred initial therapy in mantle-cell lymphoma.

Authors:  Peter Martin; Amy Chadburn; Paul Christos; Karen Weil; Richard R Furman; Jia Ruan; Rebecca Elstrom; Ruben Niesvizky; Scott Ely; Maurizio Diliberto; Ari Melnick; Daniel M Knowles; Selina Chen-Kiang; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

9.  Primary Sjögren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia.

Authors:  Stelios F Assimakopoulos; Sotiria Michalopoulou; Maria Melachrinou; Nikolaos Giannakoulas; Christos Papakonstantinou; Alexandra Lekkou; Charalambos Gogos
Journal:  Am J Med Sci       Date:  2007-12       Impact factor: 2.378

Review 10.  Rituximab in the treatment of autoimmune haematological disorders.

Authors:  Bernadette Garvey
Journal:  Br J Haematol       Date:  2008-03-03       Impact factor: 6.998

View more
  4 in total

Review 1.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

2.  Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated.

Authors:  Salih Yürek; Beate Mayer; Mohammed Almahallawi; Axel Pruss; Abdulgabar Salama
Journal:  Blood Transfus       Date:  2015-06-16       Impact factor: 3.443

3.  Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2011-04-10

4.  A case of primary ovarian lymphoma with autoimmune hemolytic anemia achieving complete response with Rituximab-based combination chemotherapy.

Authors:  N S Ghadyalpatil; R Chandrasekar; D Snehalatha; B M Reddy
Journal:  Indian J Med Paediatr Oncol       Date:  2011-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.